Search...
Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat
I'm PortAI, I can summarize articles.
Vanda Pharmaceuticals reported positive results from a study on tradipitant for nausea and vomiting prevention related to Wegovy. Analysts are optimistic, with B Riley and H.C. Wainwright reiterating Buy ratings and price targets of $11 and $20, respectively. Jefferies maintains a Hold rating with a $5 target. The study showed a 50% reduction in vomiting with tradipitant compared to placebo. Vanda's stock fell 4.97% to $4.88.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments